
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing sucralfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing sucralfate are listed in tablet and suspension forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Sucralfate is a mucosal protectant that compounding pharmacies prepare as oral suspensions, mouth rinses, rectal preparations and topical creams by prescription.
Sucralfate is an aluminum salt of sucrose octasulfate. It is a protectant, not an acid reducer: in an acidic environment it forms a sticky gel that binds to damaged tissue, covering an ulcer or sore surface and shielding it from acid, pepsin and bile salts while the tissue heals. It also binds growth factors to the injured surface and stimulates protective mucus, and very little is absorbed. Manufactured sucralfate comes as Carafate tablets and oral suspension and generics. The Carafate label states it is FDA-approved for short-term treatment of active duodenal ulcer, and the tablet is also used to prevent recurrence. A prescriber might order compounded sucralfate as a mouth rinse, a rectal enema or suppository, a topical cream, or a liquid without the glucose or flavoring in the manufactured suspension. Compounded preparations are not FDA-approved and require a prescription.
Sucralfate has no boxed warning. The Carafate label warns that it is for oral use only: fatal lung and brain emboli have occurred when it was mistakenly given intravenously. Small amounts of aluminum are absorbed, so people with chronic kidney failure or on dialysis can accumulate it, leading to bone disease or confusion; aluminum antacids add to that load. The suspension has caused high blood sugar in people with diabetes. Sucralfate binds other medicines in the gut and lowers absorption of cimetidine, digoxin, fluoroquinolones, ketoconazole, levothyroxine, phenytoin, quinidine, ranitidine, tetracycline and theophylline, so take those at least 2 hours before sucralfate, and keep antacids half an hour away. Animal studies showed no fetal harm, but human data are lacking. LactMed considers sucralfate acceptable during breastfeeding because it is virtually unabsorbed. Constipation is the most common side effect; for any side effect, talk to your prescriber or pharmacist.
Sucralfate's definitive mechanism is not established; in vitro it adsorbs pepsin, forms a polyanionic gel that adheres to proteinaceous exudate at the lesion, blocks hydrogen ion diffusion, binds bile salts, increases mucus hydrophobicity, viscosity and bicarbonate output, and binds growth factors to tissue. In humans it inhibited gastric pepsin activity by 32%. About 5% of an oral dose is absorbed; onset is 1 to 2 hours with duration up to 6 hours, breakdown to aluminum and sucrose octasulfate occurs in the gut rather than the liver or kidney, and absorbed sulfated disaccharides are excreted in urine. Labeled indication: Carafate suspension for short-term treatment of active duodenal ulcer. Prescribers have ordered compounded sucralfate suspension as a mouth rinse for chemotherapy-induced mucositis and Behçet oral ulcers, as a paste enema for hemorrhagic radiation proctitis, as a topical for venous ulcers, dermatitis and burns, and for post-adenotonsillectomy pain in children, uses StatPearls lists as off-label. Strength, vehicle and route are per prescriber. Monitoring: blood glucose in diabetics on the glucose-containing suspension, renal function and serum aluminum in CKD or dialysis patients, and separation from drugs with narrow absorption windows. Sucralfate is not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally